Lincoln Pharmaceuticals share news, announcements and annual reports
NSE: LINCOLNBSE: 531633Pharmaceuticals & BiotechnologySmall Cap
Lincoln Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1996 on BSE, Dec 2015 on NSE
Last close ₹558.10up ₹8.05 (1.46%)BSE ₹557.55
Share price at the NSE close on 28 Oct 2026. Previous close ₹550.05.
28 Oct: open ₹541.00, high ₹560.00, low ₹532.00
52-week range of traded prices to 28 Oct 2026
₹440.00Low, 28 Jan 2026₹770.00High, 27 May 2026
- Next results date: the board meets on 29 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,118 Cr1,389th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 11.59
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.48
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.32%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 11.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 47,20541.0% delivered
Lincoln Pharmaceuticals disputes and clarifications
17 filed, newest first.
Apr 2026
Jan 2026
7 Jan · Legal
Exchange has sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jul 2025
Jun 2025
23 Jun · Legal
Exchange has sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Mar 2025
4 Mar · Legal
Exchange has sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 31-Dec-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Dec 2024
11 Dec · Legal
Exchange has sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 30-Sep-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.6 Dec · Legal
The exchange asked on 6 Dec 2024
6 Dec · Legal
The exchange asked on 3 Dec 2024
Jan 2024
11 Jan · Legal
The exchange asked on 11 Jan 2024
Apr 2021
30 Apr · Legal
The exchange asked on 29 Apr 2021
Apr 2020
1 Apr · Legal
The exchange asked on 31 Mar 2020
Apr 2019
3 Apr · Legal
Exchange has sought clarification from Lincoln Pharmaceuticals Limited with respect to announcement dated 28-Mar-2019, regarding " Lincoln Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr Darshit Ashvinkumar Shah as Chief Financial Officer of the company w.e.f. March 28, 2019.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment) The response of the Company is awaited.
Jun 2018
11 Jun · Legal
Exchange has sought clarification from Lincoln Pharmaceuticals Limited with respect to announcement dated 08-Jun-2018, regarding " Lincoln Pharmaceuticals Limited has informed the Exchange that 'Effective from June 8, 2018, Shri Rajnikant G. Patel [DIN: 00104786] will act as a Non-Executive Director [Promoter Category] of the Company.'.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment); The response of the Company is awaited.